| abstract |
The present invention relates to the use of a fasted oral dosage form, more particularly (1S, 2S, 3R, 5S) -3- [7 - {[(1R, 2S) -2- (3,4- difluorophenyl) cyclopropyl] Amino] -5- (propylthio) -3H- [1,2,3] -triazolo [4,5- d] pyrimidin- 3-yl] -5- (2-hydroxyethoxy) cyclopentane- 1,2-diol, and disintegration excipients. Blister packs suitable for use with oral and oral dosage forms are also disclosed. |